Free Trial
ASX:OSL

OncoSil Medical (OSL) Stock Price, News & Analysis

OncoSil Medical logo

About OncoSil Medical Stock (ASX:OSL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.17 million shs
Average Volume
N/A
Market Capitalization
$32.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Receive OSL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSil Medical and its competitors with MarketBeat's FREE daily newsletter.

OSL Stock News Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
OncoSil Medical Expands Global Reach and Financial Strength
Oncosil Medical Ltd (OSL)
See More Headlines

OSL Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoSil Medical investors own include Invictus Energy (IVZ), Citizens (CIA), Red Mountain Mining (RMX), National Australia Bank (NAB), Rivian Automotive (RIVN), Blackmores (BKL) and Twitter (TWTR).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:OSL
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,910,000.00
Net Margins
-2,395.37%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.57 million
Price / Cash Flow
10.91
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,780,000,000
Free Float
N/A
Market Cap
$32.25 million
Optionable
Not Optionable
Beta
0.91
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (ASX:OSL) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners